News

The executive director of the newly launched Association of Movement Disorder Advanced Practice Providers provided an overview of the organization and what it can offer to APPs. [WATCH TIME: 4 minutes]

Data from the phase 3 KINECT-HD study of valbenazine (Neurocrine Biosciences) provided a keen understanding of the threshold for clinically meaningful improvement in TMC scores. The VMAT2 inhibitor showed promising gains for patients.

At CMSC 2023, the Melissa and Paul Anderson President’s Distinguished Professor of Neurology at the Perelman School of Medicine of the University of Pennsylvania, talked about the phase 2 trials that show promising results for BTK inhibitors as a potential MS therapy. [WATCH TIME: 4 minutes]

The panel of movement disorder specialists and dermatologists offered a framework of suggestions for the supervision of the most common infusion-site reaction associated with these therapies.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is Parkinson disease and related disorders.

Data from an interventional survey suggest that patients with a better understanding of social participation’s benefits may be more confident to participate in social situations and events.

A survey of more than 700 Parkinson disease caregivers highlighted the impact their role has on them emotionally, physically, and mentally, and pointed to several areas of need for support from the clinical community.

The assistant professor of neurology and director of the Movement Disorders Outreach Program at Mount Sinai Medical Center spoke about the challenges with access to care in movement disorders. [WATCH TIME: 2 minutes]

Over a 5-year period in a study, both insomnia protective and risk factors in adults were observed as significantly associated with the sleep disorder, offering valuable insights for prevention strategies.

The professor of neurology and residency program director at MedStar Georgetown University Hospital discussed the value of educating clinicians on the utility of botulinumtoxins in PD care. [WATCH TIME: 3 minutes]

Neurology News Network for the week ending June 10, 2023. [WATCH TIME: 3 minutes]

The FDA is set to make a final decision in July 2023, and if approved, lecanemab would join aducanumab as the only antiamyloid therapies available to treat early-stage Alzheimer disease.

The director of the Movement Disorders Division at Loma Linda University discussed the importance of understanding good ON time in Parkinson disease care, and how it can influence quality of life. [WATCH TIME: 5 minutes]

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending June 9, 2023.

John Harsh, PhD, clinical research director, Colorado Sleep Institute, sat down at SLEEP 2023 to discuss the RESTORE study results, and why patients with narcolepsy appear to prefer once-nightly sodium oxybate.

The sleep epidemiologist and assistant professor at the Rollins School of Public Health at Emory University, insight on the associations between race, socioeconomic backgrounds, and poor sleep and insufficient sleep. [WATCH TIME: 2 minutes]

The hold comes nearly a month after Health Canada sent PepGen a No Objection Letter to start its phase 2 CONNECT1-EDO51 trial in patients with Duchenne muscular dystrophy.

After discussions with the FDA, the study will assess 2 co-primary end points of change in Rett Syndrome Behavior Questionnaire total score and Clinical Global Impression Improvement Scale score.

The professor of neurology at the University of Virginia discussed the progress made in recognizing and diagnosing neuromyelitis optica spectrum disorder through the discovery of specific monoclonal antibodies. [WATCH TIME: 5 minutes]

Patients given slow oscillatory transcranial direct current stimulation during sleep recalled significantly more words 2 hours post-awakening compared with the sham group.

The course director of ATMRD 2023 provided perspective on the notable strides made in the movement disorder field, including the significant progress made in drug delivery. [WATCH TIME: 5 minutes]

Patients on twice-nightly oxybate reported more issues with inconvenience, anxiety, and feeling somewhat, quite a bit, or extremely groggy/unsteady the next morning.

The chief of the Sleep Disorders Clinical Research Program at Massachusetts General Hospital provided insight on new updates to the management of restless legs syndrome, including removing dopamine agonists as first line treatments. [WATCH TIME: 8 minutes]

The study did not meet its primary end point of change from baseline in Performance of the Upper Limb 2.0 score at 1 year.

At the conclusion of the analysis, lemborexant was shown to be safe, with significant improvements seen in REM latency, total REM sleep, and other measures.

Preclinical findings show the potential of samelisant, a potent and orally active Histamine H3 receptor inverse agonist, as a potential treatment for patients with Parkinson disease who experience excessive daytime sleepiness.

According to a recent study presented at SLEEP 2023, the decline in MOCA scores in patients with mild cognitive impairment was associated with the degree of hypoxia observed from sleep studies.

The course directors of the 2023 ATRMD Congress provided an overview of the upcoming meeting, and the educational benefits clinicians can gain from attending. [WATCH TIME: 6 minutes]

The chief medical officer of Harmony Biosciences provided perspective on a proof-of-concept study assessing pitolisant’s (Wakix) clinical benefit in reducing excessive daytime sleepiness individuals with Prader-Willi syndrome.

Carolyn H. Goldschmidt, DO, a neurologist at NorthShore University Health System in Chicago, talked about a retrospective study analyzing disease-modifying therapies in multiple sclerosis patients at CMSC 2023.